PTACH [NCH 51]
90 CHF CHF 90.00
AG-CR1-3667-M0055 mgCHF 90.00
AG-CR1-3667-M02525 mgCHF 320.00
|Synonyms||Cpd 51; S-(7-Oxo-7-((4-phenylthiazol-2-yl)amino)heptyl) 2-methylpropanethioate|
|Purity Chemicals||≥97% (HPLC)|
|Solubility||Soluble in DMSO (25mg/ml) or ethanol (10mg/ml). Insoluble in water.|
|Identity||Determined by 1H-NMR.|
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||-20°C|
Keep cool and dry.
Protect from light and moisture.
|Use/Stability||Stable for at least 2 years after receipt when stored at -20°C.|
|Product Specification Sheet|
- Potent non-hydroxamate HDAC inhibitor (HDACi) (IC50: 32, 48 and 41nM for HDAC4, HDAC1 and HDAC6, respectively).
- Cell permeable prodrug that is intracellularly converted to the potent HDAC inhibitor NCH 31.
- Predicted to exhibit a similar HDAC binding mode as that of SAHA, interacting with the active-site zinc targeting group.
- Shown to exhibit comparable antiproliferative and apoptotic activity as SAHA against various cancer cell lines. Inhibits growth of various cancer cells in vitro (EC50=1.1 - 9.1μM).
- Reactivates latent HIV-1 gene expression.
- Active against selected neurodevelopmental disorders.
- Normalizes neuronal impairment and neurodegeneration caused by ATP6V1A deficit.
- Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates: T. Suzuki, et al.; J. Med. Chem. 48, 1019 (2005)
- Proteome analyses of the growth inhibitory effects of NCH-51, a novel histone deacetylase inhibitor, on lymphoid malignant cells: T. Sanda, et al.; Leukemia 21, 2344 (2007)
- Identification of a potent and stable antiproliferative agent by the prodrug formation of a thiolate histone deacetylase inhibitor: T. Suzuki, et al.; Bioorg. Med. Chem. Lett. 17, 1558 (2007)
- Novel histone deacetylase inhibitor NCH-51 activates latent HIV-1 gene expression: A.F. Victoriano, et al.; FEBS Lett. 585, 1103 (2011)
- Immunological and pharmacological strategies to reactivate HIV-1 from latently infected cells: a possibility for HIV-1 paediatric patients? M. Martinez-Bonet, et al.; J. Virus Erad. 1, 148 (2015)
- Altered neuronal network and rescue in a human MECP2 duplication model: S. Nageshappa, et al.; Mol. Psychiatry 21, 178 (2016)
- Transformative Network Modeling of Multi-omics Data Reveals Detailed Circuits, Key Regulators, and Potential Therapeutics for Alzheimer’s Disease: M. Wang, et al.; Neuron 109, 257 (2021)